Women pioneering change in biotech and protein production
Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.
List view / Grid view
Alex Bonnyman is transforming protein manufacturing while championing women in STEM. Explore her journey of innovation, resilience, and inclusivity in biotechnology.
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
Discover the latest in SARS-CoV-2 antibody research as we cover three of the most recent developments in this article.
The DREP-S vaccine candidate was found to be the most potent of the two investigational vaccine prototypes, eliciting high titers of SARS-CoV-2 neutralising antibodies after a single dose.
A new MVA-based vaccine has shown success at inducing COVID-19 antibody and T-cell responses in pre-clinical studies.
The novel haptenised SARS-CoV-2 s-Spike vaccine, BVX-0320, stimulated mice to create neutralising antibodies that were able to reduce SARS-CoV-2 plaques in a neutralisation test.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
The natural language processing model trained using viral protein sequence data was able to predict promising targets for vaccines against HIV, influenza and coronaviruses.
A new protein-based nanoparticle vaccine protected mice against a variety of coronaviruses, researchers have shown.
Scientists report their phage-based inhaled vaccine delivery system elicited a robust antibody response in both mice and non-human primates.
Two new studies suggest that SARS-CoV-2-specific IgA antibodies are more neutralising and therefore COVID-19 vaccines should encourage an IgA response.
Administering two doses of a COVID-19 vaccine called BVX-0320 is effective in mouse models, a pre-clinical study has shown.
Professor Laurence D Hurst explains why understanding the nucleotide mutations in viruses, including SARS-CoV-2, can have significant implications for vaccine design.
Having analysed the SARS-CoV-2 genomes from over 46,723 patients, researchers have found no mutations that increase transmissibility.
Hamster challenge study results suggests the oral COVID-19 vaccine induces a robust immune response, protecting the animals from infection.